骨髓间充质干细胞在多发性骨髓瘤活动与缓解期具有不同的促血管生成能力

背景：活动期和缓解期多发性骨髓瘤患者骨髓间充质干细胞的血管生成能力有无差异目前尚不清楚。目的：观察多发性骨髓瘤活动期及缓解期骨髓间充质干细胞促血管生成能力的差异。方法：抽取13例多发性骨髓瘤患者治疗前和4个周期治疗后的骨髓，分离培养出骨髓间充质干细胞，采用ELISA 方法测定骨髓间充质干细胞培养上清液中血管内皮生长因子、肝细胞生长因子、碱性成纤维细胞生长因子的浓度；MTT检测骨髓间充质干细胞培养上清液对脐静脉内皮细胞增殖能力的影响；通过Transwel 小室观察骨髓间充质干细胞培养上清液对脐静脉内皮细胞运动能力的影响；通过人工基底膜实验观察骨髓间充质干细胞体外促血管生成和成管能力。结果与结论：活动期多发性骨髓瘤患者骨髓间充质干细胞培养上清中血管内皮生长因子、肝细胞生长因子、碱性成纤维细胞生长因子浓度明显高于缓解期（P〈0.05）；骨髓瘤患者骨髓间充质干细胞上清对脐静脉内皮细胞增殖作用呈剂量依赖性，活动期明显强于缓解期（P〈0.05）；活动期骨髓瘤患者骨髓间充质干细胞上清对脐静脉内皮细胞迁移作用明显高于缓解期（P〈0.05）；骨髓瘤患者骨髓间充质干细胞体外具有明显成血管作用，活动期明显强于缓解期（P〈0.05）。结果提示多发性骨髓瘤活动期骨髓间充质干细胞促血管生成能力明显大于缓解期。

Different pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state

BACKGROUND：Recent studies have found that bone marrow mesenchymal stem cells play an important role in the development of multiple myeloma, especial y for angiogenesis, but whether the pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state is different is yet unclear. OBJECTIVE：To investigate the difference in the pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state. METHODS：Bone marrow samples were extracted from 13 patients with multiple myeloma before treatment and after four therapeutic cycles to isolate bone marrow mesenchymal stem cells. ELISA assay was used to detect levels of vascular endothelial growth factor, hepatocyte growth factor and basic fibroblast growth factor in the supernatant of bone marrow mesenchymal stem cells. The proliferative ability and movement of human umbilical vein endothelial cells cultured in the supernatant of bone marrow mesenchymal stem cells were detected by MTT assay and Transwel assay, respectively. The pro-angiogenesis ability of bone marrow mesenchymal stem cells was measured by Matrigel in vitro. RESULTS AND CONCLUSION：The levels of vascular endothelial growth factor, hepatocyte growth factor and basic fibroblast growth factor in the cellsupernatant were significantly higher in active myeloma than those in remissive myeloma （P〈0.05）. The supernatant of bone marrow mesenchymal stem cells of active myeloma more significantly promoted the proliferation, migration and blood vessel formation of human umbilical vein endothelial＆amp;nbsp;cells than that of remissive myeloma in a dose-dependent manner （P〈0.05）. These findings indicate that bone marrow mesenchymal stem cells from active myeloma have stronger pro-angiogenesis ability than those from remissive myeloma.